Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice

Atherosclerosis

Volumn 216, Issue 2, 2011, Pages 313-320

  Bhaskar, Vinay ^a   Yin, Johnny ^a   Mirza, Amer M ^a   Phan, Dan ^a   Vanegas, Sandra ^a   Issafras, Hassan ^a   Michelson, Kristen ^a   Hunter, John J ^a   Kantak, Seema S ^a  

^a XOMA Corporation   (United States)

Author keywords

ApoE deficient mouse; Atherosclerosis; Cytokines; IL 1 beta; Inflammation; Monoclonal antibody; XOMA 052

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; GELATINASE B; GEVOKIZUMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; ANTIBODIES, MONOCLONAL; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BODY WEIGHT; COCULTURE TECHNIQUES; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-1BETA; LIPIDS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, SMOOTH MUSCLE; PLAQUE, ATHEROSCLEROTIC;

EID: 79955649518     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.026     Document Type: Article

References (21)

1. Dinarello C.A. Blocking IL-1 in systemic inflammation. J Exp Med 2005, 201:1355-1359.
2. Apostolakis S., Vogiatzi K., Krambovitis E., Spandidos D.A. IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications. Cardiovasc Hematol Agents Med Chem 2008, 6:150-158.
3. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
4. Chamberlain J., Francis S., Brookes Z., et al. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 2009, 4:e5073.
5. Devlin C.M., Kuriakose G., Hirsch E., Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A 2002, 99:6280-6285.
6. Kirii H., Niwa T., Yamada Y., et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:656-660.
7. Libby P., Aikawa M. New insights into plaque stabilisation by lipid lowering. Drugs 1998, 56(Suppl 1):9-13. discussion 33.
8. Owyang A.M., Maedler K., Gross L., et al. XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology 2010, 151:2515-2527.
9. Roell M.K., Issafras H., Bauer R.J., et al. A kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1 beta (IL-1{beta}) activity. J Biol Chem 2010, 285:20607-20614.
10. Abbate A., Van Tassell B.W., Seropian I.M., et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 2010, 12:319-322.
11. Calkin A.C., Giunti S., Sheehy K.J., et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 2008, 51:1731-1740.
12. Johnson J.L., Baker A.H., Oka K., et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006, 113:2435-2444.
13. Worley J.R., Baugh M.D., Hughes D.A., et al. Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem 2003, 278:51340-51346.
14. Lee Y.W., Hirani A.A. Role of interleukin-4 in atherosclerosis. Arch Pharm Res 2006, 29:1-15.
15. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
16. Isoda K., Sawada S., Ayaori M., et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Biol Chem 2005, 280:7002-7009.
17. Libby P., Sukhova G., Lee R.T., Galis Z.S. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995, 25Suppl2:S9-12.
18. Ehses J.A., Lacraz G., Giroix M.H., et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009, 106:13998-14003.
19. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
20. Isoda K., Sawada S., Ishigami N., et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004, 24:1068-1073.
21. Mandrup-Poulsen T., Pickersgill L., Donath M.Y. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010, 6:158-166.